Trial Profile
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Nintedanib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 26 Feb 2009 Results were presented at 2009 Genitourinary Cancers Symposium.
- 04 Feb 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 02 Oct 2008 Planned number of patients changed from 80 to 87, based on information from ClinicalTrials.gov.